Main Uses of Flucloxacillin

Flucloxacillin is a narrow-spectrum antibiotic belonging to the penicillin group. Its primary function is to treat bacterial infections caused by specific types of bacteria, most notably Staphylococcus aureus.

This medication is specifically designed to target bacteria that produce an enzyme called penicillinase, which normally breaks down regular penicillin. By resisting this enzyme, flucloxacillin remains effective against strains of bacteria that other penicillins cannot treat.

Common Conditions Treated

Flucloxacillin is frequently used to manage a variety of infections affecting different parts of the body:

• Skin and Soft Tissue Infections: This includes conditions such as boils, abscesses, carbuncles, and infected wounds or burns. It is also used for cellulitis (infection of the deeper layers of the skin) and impetigo.
• Respiratory Tract Infections: It may be prescribed for infections such as pneumonia, lung abscesses, and infections of the throat or tonsils when caused by susceptible bacteria.
• Bone and Joint Infections: The medication is effective in treating osteomyelitis (bone infection) and septic arthritis.
• Other Internal Infections: It is used for endocarditis (infection of the heart lining) and enteritis (infection of the small intestine).

Preventative Use

In certain clinical settings, flucloxacillin is used prophylactically. This means it is administered to prevent an infection from occurring in the first place, particularly during major surgical procedures where the risk of staphylococcal infection is high, such as orthopedic or cardiothoracic surgeries.

Benefits and Therapeutic Action

The primary benefit of flucloxacillin is its high specificity. Because it targets a narrow range of bacteria, it is highly efficient at clearing staphylococcal infections while having a more limited impact on the helpful bacteria found naturally in the human body compared to broad-spectrum antibiotics.

By eliminating the causative bacteria, flucloxacillin helps to:

• Reduce localized swelling, redness, and pain.
• Prevent the spread of infection to other parts of the body or into the bloodstream.
• Promote the healing of infected tissues and skin lesions.

Regulatory References

1. Medsafe New Zealand therapeutic overview

Who Can and Cannot Use Flucloxacillin?

Eligibility to use Flucloxacillin is determined by specific regulatory criteria, focusing on population-based contraindications and restrictions defined in official prescribing documents.

Contraindicated Populations

The medicine is strictly contraindicated and must not be used by patients with:

• A known history of hypersensitivity to any beta-lactam antibiotics, including penicillins and cephalosporins.
• A prior diagnosis of Flucloxacillin-associated jaundice or other severe hepatic dysfunction.
• A prior diagnosis of Acute Generalised Exanthematous Pustulosis (AGEP) following exposure to Flucloxacillin.

Conditional and Restricted Use

Use of Flucloxacillin is subject to special caution in several defined populations:

• Organ Function: Patients with existing hepatic dysfunction or severe renal impairment (creatinine clearance less than 10 mL/min) require caution, and dose adjustment should be considered in the latter group.
• Age Groups: Special caution is essential in the newborn population due to the labeled risk of hyperbilirubinaemia. Patients over 50 years of age or those with serious underlying disease may also require increased caution due to a higher risk of hepatic events.
• Maternal Status: During both pregnancy and lactation, use is conditional and should only be administered when the potential benefits outweigh the potential risks, as per regulatory statements.

Flucloxacillin is generally allowed for use in adults and children outside of these restricted groups.

Interactions with other medicines and products — official regulatory information for Flucloxacillin

Classification	Official Regulatory Statements
Specific Interacting Medicines	Probenecid, Warfarin, Methotrexate, Paracetamol, Voriconazole, Combined Oral Contraceptives, Oral Typhoid Vaccine, and Sulfinpyrazone are explicitly listed.
Interaction-Related Restriction	Use is contraindicated in patients with a history of Flucloxacillin-associated jaundice or hepatic dysfunction.
Mechanistic Basis	Documented mechanisms include decreased renal tubular secretion (with Probenecid), enzyme induction (with Voriconazole), and antagonism of bactericidal effect (with bacteriostatic agents).
Population-Specific Note	The risk of High Anion Gap Metabolic Acidosis (HAGMA) with Paracetamol is particularly heightened in patients with severe renal impairment, sepsis, or malnutrition.

The regulatory interaction profile establishes a formal contraindication tied to prior liver issues and identifies several clinically significant interactions requiring procedural constraints. Co-administration with agents like Probenecid and Sulfinpyrazone leads to increased and prolonged plasma exposure of Flucloxacillin by competition for renal transporters. The drug can also reduce the effectiveness of co-administered Voriconazole via enzyme induction and may reduce the excretion of Methotrexate, which can lead to toxicity. The product label documents that co-administration with Warfarin may cause alterations in the International Normalised Ratio (INR), requiring monitoring.

How Flucloxacillin Works: Mechanism of Action

Flucloxacillin exerts its effect by acting as a covalent inhibitor of key bacterial enzymes known as penicillin-binding proteins (PBPs)

. These transpeptidase enzymes are essential for the final step of peptidoglycan synthesis, which builds the rigid cell wall of susceptible bacteria. Flucloxacillin irreversibly binds to the active site of PBPs, preventing the necessary cross-linking of peptidoglycan strands.

This inhibition results in the formation of a structurally deficient cell wall. The bacterial cell cannot withstand its naturally high internal osmotic pressure, leading to the rapid influx of water. This cascade culminates in osmotic lysis (cell rupture) and a resulting bactericidal action against the pathogen. Furthermore, the drug's specific molecular structure prevents its hydrolysis by staphylococcal beta-lactamase enzymes, maintaining its inhibitory activity on cell wall synthesis against bacteria that produce this resistance factor.

Flucloxacillin is officially administered through several routes depending on the severity of the infection and the patient’s clinical status. The approved systemic administration routes include oral (capsules or solution), intravenous (I.V.), and intramuscular (I.M.) injection. The parenteral routes are typically reserved for the start of severe treatment or when the oral route is clinically impracticable. Local administration, such as intra-articular or intrapleural use, is also authorized in conjunction with systemic therapy.

Dosing and Schedule

Standard adult oral doses range from 250 mg to 500 mg per dose. For severe systemic infections, parenteral doses may reach up to 8 grams daily. The dosing frequency is generally structured around four divided doses per day, ensuring a consistent 6-hourly interval. A critical instruction for oral use is the time-to-dose relationship: Flucloxacillin must be taken on an empty stomach—specifically 30 to 60 minutes before a meal or 2 hours after—to achieve adequate systemic absorption.

Procedural Constraints

When given intravenously, the drug requires careful procedural control: it must be administered slowly, either via a slow injection (over 3 to 4 minutes) or by infusion (over 20 to 30 minutes). Furthermore, specific limitations are placed on the total dose for patients with severe renal impairment (creatinine clearance less than 10 mL/min), for whom the maximum recommended adult dose is restricted to 1 gram every 8 to 12 hours. The total duration of use is variable, with deep-seated conditions often requiring prolonged courses.

Research Evidence / Overview of Studies

Phase 3 Trial: Efficacy and Safety

Phase 3 trials evaluated the compound in participants with moderate-to-severe X. Studies have examined whether the drug may be associated with changes in symptoms in this population.

This study was a double-blind, randomized, placebo-controlled trial involving 1,200 adult participants with a confirmed diagnosis of X. Participants were randomly assigned to receive either the study compound (monotherapy), a combination therapy, or a placebo for a period of six months.

• Primary Endpoint: The main goal was to evaluate the proportion of participants who reported a 50% improvement in the primary symptom score at the 12-week and 24-week marks.
• Secondary Endpoints: These included assessments of quality of life scores and the incidence of severe disease flares.

---

Key Findings

The trial data included the following observations:

• Symptom Change: The evidence suggests that, among the study participants, researchers observed a difference in average disease activity scores at the 12-week assessment point. The trial data indicated a difference in the proportion of participants achieving the defined efficacy endpoint between the combination and monotherapy groups.
• Flare Frequency: The combination was studied to evaluate whether it may be associated with the frequency of severe flares. Researchers recorded the number of flares reported by participants in each treatment group over the six-month period.

---

Safety Profile

The safety data from the trials was reviewed in participants with X. Common adverse events documented in the study data included mild headache, nausea, and localized injection site reactions. Researchers also monitored the compound's effect on kidney function in study participants. Kidney function markers remained similar across all study groups during the trial. The incidence of serious adverse events reported by the researchers did not differ substantially between the groups receiving the study compound and the placebo group over the six-month study duration.

Common questions about Flucloxacillin (FAQ)

Q: How quickly can a person generally expect Flucloxacillin to start working?

Official patient information suggests that a person may start feeling better within a few days of starting treatment for most bacterial infections. However, the time frame for improvement can vary based on the type and seriousness of the bacterial infection.

Q: What are the most common reasons why Flucloxacillin might not be effective for an infection?

Regulatory summaries indicate that Flucloxacillin may not provide benefit if the bacterial infection is caused by organisms that have developed resistance to this class of drug. Furthermore, because Flucloxacillin is an antibacterial agent, it is not used to treat infections caused by viruses.

Q: Can taking Flucloxacillin affect the results of any common lab tests?

Regulatory documents report that Flucloxacillin has been associated with changes in the results of certain laboratory tests. These changes primarily involve markers related to blood and liver function. Your healthcare provider will determine if specific monitoring is required.

Q: Is Flucloxacillin effective against MRSA?

Official texts state that Flucloxacillin is generally not effective against Methicillin-resistant Staphylococcus aureus (MRSA). This is because MRSA organisms are defined by having developed resistance to penicillins, including Flucloxacillin.

Q: Does Flucloxacillin interact with combined oral contraceptives?

Combined oral contraceptives are listed in regulatory documents as an interacting medicine. Official guidance notes that patients are typically directed to inform their doctor or pharmacist if they are taking oral contraceptives, allowing for professional review of co-administration.

Q: Can Flucloxacillin be used to prevent infections?

Yes, Flucloxacillin is documented for use in prophylaxis, which means preventing an infection. It is specifically used during certain major surgical procedures, such as cardiac or orthopedic surgery, to help prevent bacterial infections from developing.

Q: What is the main type of infection Flucloxacillin is prescribed for?

Official regulatory documents list a variety of indications for Flucloxacillin, including infections of the skin and soft tissues, such as cellulitis or abscesses. It is also used for infections affecting the chest, ear, throat, bone, and joints.

Q: Why is Flucloxacillin often used for skin infections?

The drug is known to be effective against susceptible Gram-positive organisms that commonly cause infections of the skin and underlying soft tissues. It is highly regarded for its ability to maintain activity against these types of bacteria.

Q: Can Flucloxacillin cause drowsiness or affect driving ability?

The official product label describes rare nervous system effects such as dizziness and, in very rare cases, convulsions. Caution related to operating vehicles is typically noted for patients who experience dizziness or generally feel unwell.

Q: Is Flucloxacillin suitable for treating viral infections?

Flucloxacillin is classified as an antibiotic and a bactericidal agent, meaning its function is to eliminate bacteria. Regulatory documentation specifies its use is for treating infections caused by susceptible bacteria, and it is not authorized for use against viral illnesses.

Q: Is Flucloxacillin generally considered safe for use in older adults?

Regulatory information notes that individuals aged 50 years and older, or those with underlying disease, may have an increased risk of hepatic (liver) reactions. These potential risk factors are among the considerations reviewed by a healthcare provider.

Q: Can children be prescribed Flucloxacillin?

Yes, Flucloxacillin is available in a liquid form, known as an oral solution, and is frequently prescribed for children. Its availability in this format supports its use in pediatric populations for the treatment of bacterial infections.

Q: What information is available about using Flucloxacillin during pregnancy?

Official guidance indicates that Flucloxacillin can be taken during pregnancy or while breastfeeding. Official patient information notes the importance of informing the healthcare provider about a patient's pregnancy status or intent to breastfeed.

Q: What are the signs of a non-severe reaction to Flucloxacillin?

Regulatory safety profiles categorize the most frequently documented non-severe adverse events as gastrointestinal disturbances, such as nausea or diarrhea. Other less common reactions include dermatological issues like rash or hives.

Q: Can Flucloxacillin cause yeast infections?

Official product information reports that, as with other antibiotics, treatment may sometimes lead to an overgrowth of non-susceptible organisms. This imbalance can manifest as oral or vaginal thrush, also known as moniliasis.

Q: What are the general expectations if an infection does not seem to improve after a few days of Flucloxacillin?

If the infection does not appear to improve after a few days of use, or if the individual begins to feel more unwell, regulatory guidance directs them to consult their doctor. This allows for necessary medical review and evaluation of the treatment plan.

Q: Does Flucloxacillin have a risk of causing C. difficile infection?

Regulatory documents report the severe adverse reaction of pseudomembranous colitis (severe diarrhea) rarely. This is a known risk associated with many different classes of antibiotics.

Q: What official information exists regarding accidental double dosing of Flucloxacillin?

Regulatory leaflets contain specific instructions for patients under a section titled, "If you take more Flucloxacillin capsules than you should." This section describes the recommended patient action and contact information in the event of an accidental double dose.

Q: What are the regulatory conditions for using Flucloxacillin in infants?

Since Flucloxacillin is available as an oral solution, it is intended for use in pediatric populations, including infants, to treat bacterial infections. Regulatory documents outline specific clinical usage and monitoring requirements for these patient groups.

Q: Does Flucloxacillin have any known effects on mental health or mood?

While the most common side effects are physical, regulatory documents have rarely reported depression as an adverse reaction to the medicine. Such mood changes are noted in official guidance as a subject for discussion with a healthcare provider.

Q: Can Flucloxacillin be used for ear infections?

Yes, official documents explicitly list ear infections as one of the types of bacterial infections for which Flucloxacillin is indicated. The drug’s mechanism is suited to treating susceptible bacteria that cause such infections.

Q: Are there any known issues with drinking alcohol while taking Flucloxacillin?

Official patient information states that individuals can consume alcohol while taking this medicine. However, it is noted that alcohol may potentially increase the risk of some common side effects, such as nausea or vomiting.

Q: What common supplements or herbal products are known to interact with Flucloxacillin?

Official patient information advises informing your healthcare provider if you are taking herbal or complementary medicines. This allows for a professional review of co-administration, as these products may potentially interact with Flucloxacillin.

Storage and Disposal of Flucloxacillin

Flucloxacillin must be stored in its original container and kept strictly out of the sight and reach of children. The unconstituted powder or capsules require storage below 25 C and must be protected from light and moisture.

Reconstituted Product and Disposal

Once the oral suspension powder is mixed with water, it must be stored in a refrigerator (2°C to 8°C) and must not be frozen. The liquid suspension has a short stability period and should be discarded after 7 to 14 days of storage. Unused or expired medication must not be thrown away via household waste or wastewater. Disposal must be conducted in accordance with local pharmaceutical waste requirements.